The Clorox Company
NYSE:CLXHousehold & Personal Products
-$2.54 today
- Market cap
- $13.13B
- Beta
- 0.55
- P/E (TTM)
- 15.2
- EPS (TTM)
- $6.23
- Dividend yield
- 5.22%
Volume 2.16M
Average 2.84M
CLX Net Receivables
Amounts owed to the company by customers and others, net of allowances for uncollectible accounts.
The Clorox CompanyNYSE: CLX
Net Receivables · Q1 FY2027 · quarter ended Sep 2026
Net receivables rises 6.0% from a year ago
Net receivables stood at $745M at the end of Q1 FY2027, up 6.0% from a year earlier and down 5.8% from the prior quarter. Over 3 fiscal years it compounded at +4.8% a year.
Context
- Net receivables amounted to 9.5% of total assets at the end of Q1 FY2027, down 3.2 pp from a year earlier.
- Net receivables increased in 2 of the last 3 fiscal years.
What to watch
Whether net receivables keeps rising in the next quarterly balance sheet after a +6.0% change from a year earlier.
Sources:Balance SheetText generated from reported figures; not investment advice.
Net Receivables history
USD · from the balance sheet
- Latest · FY2026
- 791M USD
- Year-over-year change
- -3.7%
- 4-year CAGR
- +3.8%
| Period | Period end | Net Receivables | YoY change |
|---|---|---|---|
| FY2026 | 2026-06-30 | 791M | -3.7% |
| FY2025 | 2025-06-30 | 821M | +18.1% |
| FY2024 | 2024-06-30 | 695M | +1.0% |
| FY2023 | 2023-06-30 | 688M | +1.0% |
| FY2022 | 2022-06-30 | 681M | — |
Net Receivables vs competitors
How CLX compares with its peers on the latest reported figures
- Peers report in different currencies, so net receivables is compared through growth and share of total assets rather than absolute size.
- Its year-over-year change of +6.0% is the 4th highest of 11, against a peer median of +5.0%.
- Net receivables amounts to 9.5% of total assets for CLX, versus a peer median of 9.7%.
| Company | Period | Latest balance | YoY | 3-year CAGR | % of assets |
|---|---|---|---|---|---|
| Dec 2025 | €7.67B EUR | +49.9% | +19.1% | 10.9% | |
| Sep 2026 | $6.62B USD | +2.1% | +3.4% | 5.0% | |
| Sep 2026 | $2.5B USD | -15.0% | +7.0% | 9.4% | |
| Sep 2026 | $1.9B USD | +5.2% | +3.7% | 11.4% | |
| Jun 2026 | $1.86B USD | -7.4% | -6.0% | 10.0% | |
| Sep 2026 | $745M USD | +6.0% | +4.8% | 9.5% | |
| Jun 2026 | $701.6M USD | +5.9% | +18.6% | 19.6% | |
| Sep 2026 | $635.2M USD | +4.9% | +12.0% | 6.8% | |
| Jun 2026 | $374M USD | +8.7% | -0.5% | 7.4% | |
| Feb 2026 | $366.68M USD | -15.5% | -1.4% | 17.3% | |
| Mar 2026 | $267.7M USD | +13.9% | -2.3% | 7.6% | |
| Peer median (excluding CLX) | — | +5.0% | +3.5% | 9.7% | |
Competitors are the stored peer set for CLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Balance Sheet
Metric | FY2022 Jun 2022 | FY2023 Jun 2023 | FY2024 Jun 2024 | FY2025 Jun 2025 | FY2026 Jun 2026 |
|---|---|---|---|---|---|
| Cash & Equivalents | 183M | 367M | 202M | 167M | 143M |
| Short-term Investments | 0 | 0 | 0 | 0 | 0 |
| Net Receivables | 681M | 688M | 695M | 821M | 791M |
| Inventory | 755M | 696M | 637M | 523M | 777M |
| Other Current Assets | 0 | 77M | 88M | 97M | 113M |
| Total Current Assets | 1.73B | 1.83B | 1.62B | 1.61B | 1.82B |
| Property, Plant & Equipment (Net) | 1.68B | 1.69B | 1.68B | 1.6B | 1.91B |
| Goodwill | 1.56B | 1.25B | 1.23B | 1.23B | 1.95B |
| Intangible Assets | 884M | 712M | 681M | 566M | 606M |
| Long-term Investments | 0 | 0 | 0 | 0 | 0 |
| Tax Assets | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Assets | 315M | 462M | 545M | 558M | 1.51B |
| Total Non-current Assets | 4.43B | 4.12B | 4.13B | 3.95B | 5.97B |
| Total Assets | 6.16B | 5.95B | 5.75B | 5.56B | 7.79B |
| Account Payables | 960M | 1.02B | 950M | 838M | 1.6B |
| Short-term Debt | 237M | 50M | 4M | 4M | 1.09B |
| Tax Payables | 0 | 121M | 0 | 0 | 0 |
| Deferred Revenue | 0 | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 176M | 262M | 190M | 179M | 0 |
| Total Current Liabilities | 1.78B | 1.92B | 1.57B | 1.92B | 2.77B |
| Long-term Debt | 2.47B | 2.48B | 2.48B | 2.48B | 3.98B |
| Deferred Tax Liabilities | 66M | 28M | 22M | 20M | 17M |
| Deferred Revenue (Non-current) | 0 | 0 | 0 | 0 | 0 |
| Other Non-current Liabilities | 791M | 825M | 848M | 351M | 405M |
| Total Non-current Liabilities | 3.65B | 3.64B | 3.69B | 3.16B | 4.77B |
| Total Liabilities | 5.43B | 5.56B | 5.26B | 5.08B | 7.54B |
| Common Stock | 131M | 131M | 131M | 131M | 131M |
| Retained Earnings | 1.05B | 583M | 250M | 432M | 386M |
| Accumulated OCI | (479M) | (493M) | (155M) | (157M) | (157M) |
| Other Stockholders Equity | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 173M | 168M | 164M | 161M | 162M |
| Total Equity | 729M | 388M | 492M | 482M | 252M |
| Total Debt | 3.1B | 2.92B | 2.9B | 2.88B | 5.52B |
| Net Debt | 2.92B | 2.56B | 2.7B | 2.71B | 5.38B |
The Clorox Company
NYSE:CLX
Intrinsic Alpha fair value
Locked
Current Price
$108.39
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.